We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.7B
AUM Growth
-$252M
(-13%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
6
Top Buys
| 1 |
MMED
MiniMed Group Inc
MMED
|
+$17.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 3 |
Boston Scientific
BSX
|
+$9.3M |
| 4 |
HTFL
Heartflow Inc
HTFL
|
+$8M |
| 5 |
PTC Therapeutics
PTCT
|
+$7.08M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$61.1M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$45.3M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$27.4M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$24M |
| 5 |
Travere Therapeutics
TVTX
|
+$21.9M |
Sector Composition
| 1 | Healthcare | 99.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ocular Therapeutix
OCUL
$2.12B
| $3.25M | 0.19% |
383,716
+37,896
| +11% | +$361K |
|
77
Viking Therapeutics
VKTX
$4.41B
| $3.12M | 0.18% |
+96,000
| New | +$3.09M |
|
78
Cytokinetics
CYTK
$11.1B
| $2.99M | 0.18% |
45,364
+9,511
| +27% | +$604K |
|
79
Century Therapeutics
IPSC
$384M
| $2.95M | 0.17% |
+1,304,347
| New | +$2.74M |
|
80
CVS Health
CVS
$135B
| $2.87M | 0.17% |
+40,000
| New | +$3.08M |
|
81
Roivant Sciences
ROIV
$25.1B
| $2.69M | 0.16% |
97,000
+8,250
| +9% | +$212K |
|
82
Talphera
TLPH
$73.2M
| $2.68M | 0.16% |
3,589,186
| – | – |
|
83
Olema Pharmaceuticals
OLMA
$1.04B
| $2.54M | 0.15% |
170,378
+72,138
| +73% | +$1.61M |
|
84
Surgery Partners
SGRY
$1.98B
| $2.48M | 0.15% |
208,000
-102,000
| -33% | -$1.46M |
|
|
LENZ
85
LENZ Therapeutics
LENZ
$155M
| $2.36M | 0.14% |
257,460
| – | – |
|
86
Edwards Lifesciences
EW
$51.9B
| $2.31M | 0.14% |
28,900
-53,600
| -65% | -$4.42M |
|
87
Dianthus Therapeutics
DNTH
$5.54B
| $2.25M | 0.13% |
+26,757
| New | +$1.55M |
|
88
Neurogene
NGNE
$780M
| $2.1M | 0.12% |
104,339
| – | – |
|
89
Agilon Health
AGL
$2.05B
| $2.06M | 0.12% |
260,000
| – | – |
|
90
Corcept Therapeutics
CORT
$9.71B
| $2.03M | 0.12% |
50,250
| – | – |
|
91
Acadia Healthcare
ACHC
$2.91B
| $1.77M | 0.1% |
75,500
-44,500
| -37% | -$806K |
|
92
Teva Pharmaceuticals
TEVA
$37.1B
| $1.37M | 0.08% |
45,500
| – | – |
|
93
MoonLake Immunotherapeutics
MLTX
$1.63B
| $1.15M | 0.07% |
61,700
| – | – |
|
94
Jazz Pharmaceuticals
JAZZ
$15B
| $1.09M | 0.06% |
5,750
+4,000
| +229% | +$699K |
|
95
Jasper Therapeutics
JSPR
$20.2M
| $964K | 0.06% |
1,100,726
| – | – |
|
96
Legend Biotech
LEGN
$4.97B
| $733K | 0.04% |
40,500
+6,700
| +20% | +$128K |
|
97
Gossamer Bio
GOSS
$68.5M
| $529K | 0.03% |
1,609,492
-1,657,468
| -51% | -$2.61M |
|
|
FOLD
98
DELISTED
Amicus Therapeutics
FOLD
| $305K | 0.02% |
21,062
-1,908,869
| -99% | -$27.4M |
|
|
ORKA
99
Oruka Therapeutics
ORKA
$5.28B
| $202K | 0.01% |
+4,123
| New | +$143K |
|
100
BioCryst Pharmaceuticals
BCRX
$2.48B
| $120K | 0.01% |
+12,600
| New | +$97.8K |
|
Similar funds
AAM
SGI
WAS
SI
PP
SWM
AAA
FDP